Emergent BioSolutions (NYSE:EBS) Price Target Increased to $8.00 by Analysts at Benchmark

Emergent BioSolutions (NYSE:EBS) had its price target hoisted by investment analysts at Benchmark from $5.00 to $8.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Benchmark’s price target points to a potential upside of 32.01% from the company’s previous close.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $6.06 on Thursday. The firm’s 50 day moving average is $4.34 and its two-hundred day moving average is $3.00. The firm has a market capitalization of $317.54 million, a P/E ratio of -0.55 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $9.96.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. The firm had revenue of $300.40 million for the quarter. During the same quarter in the prior year, the business earned ($3.17) earnings per share. Analysts anticipate that Emergent BioSolutions will post -1.98 earnings per share for the current year.

Insider Activity at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the completion of the sale, the director now directly owns 54,482 shares of the company’s stock, valued at approximately $332,885.02. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 12,919 shares of company stock worth $75,831 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Emergent BioSolutions

A number of hedge funds and other institutional investors have recently modified their holdings of EBS. Charles Schwab Investment Management Inc. boosted its stake in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after buying an additional 1,312,934 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 356.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company’s stock valued at $2,002,000 after acquiring an additional 651,480 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Emergent BioSolutions in the 3rd quarter worth approximately $712,000. Finally, Cetera Advisors LLC bought a new stake in shares of Emergent BioSolutions in the 1st quarter worth approximately $428,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.